Carboplatin + Durvalumab + Etoposide + Olaparib
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Lung Small Cell Carcinoma
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Trial Timeline
Jan 5, 2021 → Dec 31, 2027
NCT ID
NCT04728230About Carboplatin + Durvalumab + Etoposide + Olaparib
Carboplatin + Durvalumab + Etoposide + Olaparib is a phase 1/2 stage product being developed by AstraZeneca for Extensive Stage Lung Small Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04728230. Target conditions include Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8.
What happened to similar drugs?
0 of 11 similar drugs in Extensive Stage Lung Small Cell Carcinoma were approved
Approved (0) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04728230 | Phase 1/2 | Active |
Competing Products
20 competing products in Extensive Stage Lung Small Cell Carcinoma